The Effect of Pramipexole Combined with Levodopa on Serum Hcy Expression and Muscle Tone in Patients with Parkinson's Disease
HU Rong-rong
2024, 42(7):
13-15.
Asbtract
(
74 )
PDF (1683KB)
(
25
)
References |
Related Articles |
Metrics
Objective To investigate the effect of pramipexole combined with levodopa on serum homocysteine (HCY) expression and muscle tone in patients with Parkinson's disease. Methods From September 2019 to January 2023, 86 cases of patients with Parkinson's disease who were diagnosed and treated at the Second Hospital of Weinan City were selected as the research subjects and grouped according to the principle of 1:1 randomized envelope draw, i.e., the combination group and the traditional group, each with 43 cases. The traditional group was given levodopa treatment, while the conjoined group was treated with the addition of pramipexole, Both groups were treated and observed for 3 months, and overall effective rate of treatment,incidence of adverse effects, the expression of serum homocysteine, the change of muscle tension, epileptiform discharges, changes in number of involved leads were observed and recorded. Results After 3 months of treatment, the total effective rate of the combination group were 97.67%, while the traditional group were 86.05%. The combination group were significantly higher than the traditional group (P<0.05). The incidence of postural Hypotension, somnolence, dizziness, nausea, palpitation and other adverse reactions in the combination group were 2.33%, 4.65%, 4.65% and 2.33% respectively during the three months of treatment, while those in the traditional group were 4.65%, 2.33%, 4.65% and 4.65%, respectively. There were no significant difference between the two groups (P>0.05). The muscle tone scores of the two groups after 3 months of treatment were significantly lower than before treatment (P<0.05), and the muscle tone scores of the combination group after 3 months of treatment were also significantly lower compared to the traditional group (P<0.05). Serum homocysteine levels were higher in both groups after 3 months of treatment than before treatment (P<0.05), but serum homocysteine levels were lower in the combined group than in the conventional group after 3 months of treatment (P<0.05). After 3 months of treatment, the epileptiform discharge and number of involved leads in both groups were lower than before treatment (P<0.05), while the combination group had lower epileptiform discharge and number of involved leads after 3 months of treatment than the traditional group (P<0.05). Conclusion Pramipexole combined with levodopa in patients with Parkinson's disease can improve the overall therapeutic effect, reduce the occurrence of adverse reactions, inhibit the release of serum homocysteine, improve the patient's muscle tone, and improve the patient's Electroencephalography status.
